Plasma nortriptyline and clinical response–a study using changing plasma levels

1977 ◽  
Vol 7 (1) ◽  
pp. 87-91 ◽  
Author(s):  
Graham D. Burrows ◽  
Kay P. Maguire ◽  
Bruce A. Scoggins ◽  
James Stevenson ◽  
Brian Davies
Keyword(s):  
Clinical Response ◽  
Plasma Levels ◽  
Depression Scale ◽  
Hamilton Depression Scale ◽  
The Third ◽  
Depressed Patients ◽  
Significant Relationships ◽  
Severity Of Depression

SynopsisIn a 5-week study of 22 depressed patients treated with nortriptyline, significant changes in plasma levels, both elevated and reduced, were deliberately produced in the third and fourth weeks of each patient's treatment. Correlation of plasma nortriptyline levels and changes in the severity of depression, as measured by the Hamilton Depression Scale, showed no significant relationships. The implications of the study are discussed.

Correlations for Social Support with Depression in the Chronic Poststroke Period

1997 ◽  
Vol 85 (3) ◽  
pp. 811-818 ◽  
Author(s):  
Isao Fukunishi ◽  
Takayuki Aoki ◽  
Takashi Hosaka
Keyword(s):  
Social Support ◽  
Cerebrovascular Disease ◽  
Depression Scale ◽  
Mood States ◽  
Hamilton Depression Scale ◽  
Psychological Measures ◽  
Social Support Scale ◽  
Poor Social Support ◽  
Severity Of Depression ◽  
Scale Profile

This study examined correlations of social support with rated mood states, including depression, for 47 patients with cerebrovascular disease during the chronic poststroke period. After the Structured Clinical Interview for DSM-III–R, four psychological measures, the Zung Self-depression Scale, the Hamilton Depression Scale, Profile of Mood States, and Social Support Scale, were administered. The patients with cerebrovascular disease exhibited significantly more psychiatric disorders, including depression, and had poorer social support than healthy controls. The severity of depression was significantly related to poor social support and particularly to the presence of social support rather than just the perception of poor social support. Depressed patients may also rate their support as poor because they are depressed. For some patients with cerebrovascular disease during the chronic poststroke period, depression may be related to low social support.

scholarly journals Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen

2019 ◽  
Vol 7 (2) ◽  
pp. 75-76
Author(s):  
Wiebke Sondermann
Keyword(s):  
Clinical Response ◽  
Response Rate ◽  
Depression Scale ◽  
Female Gender ◽  
Anxiety Symptoms ◽  
Anxiety And Depression ◽  
Depression Symptoms ◽  
Etanercept Treatment ◽  
Depressed Patients ◽  
Pasi Score

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

Motor activity in depressed patients during therapeutic sleep deprivation

2010 ◽  
Vol 25 (8) ◽  
pp. 465-467 ◽  
Author(s):  
T.U. Brückner ◽  
M.H. Wiegand
Keyword(s):  
Motor Activity ◽  
Sleep Deprivation ◽  
Depression Scale ◽  
Mechanisms Of Action ◽  
Activity Levels ◽  
Hamilton Depression Scale ◽  
Depressed Patients ◽  
Bidirectional Relationship ◽  
Dsm Iv ◽  
Insight Into

AbstractProblemBoth sleep and motor activity have a bidirectional relationship with depression. The existing literature on motor activity during therapeutic sleep deprivation in depressed patients is inconsistent and fragmentary. In the present study we measured motor activity continuously during 40 hours of sleep deprivation in depressed patients.MethodThirty-four inpatients suffering from a major depression (DSM-IV) underwent sleep deprivation with a continuous waking period of 40 hours. Motor activity of the patients was continuously recorded using an actigraph on the non-dominant wrist. The effect of sleep deprivation was assessed by the Hamilton Depression Scale (six-item version), thus separating the group into responders and non-responders to sleep deprivation.ResultsWe found no significant differences in motor activity between responders and non-responders on the day before sleep deprivation. During the night, responders to sleep deprivation exhibited a higher motor activity and less periods of rest. On the day after sleep deprivation, responders exhibited a higher activity, too.ConclusionsMotor activity levels differ between the two groups, thus giving more insight into possible mechanisms of action of the therapeutic sleep deprivation. We suggest that higher motor activity during the night prevents naps and leads to better response to sleep deprivation.

Amitriptyline: Comparison of Three Different Dosage Schedules in Neurotic Depression

1979 ◽  
Vol 135 (1) ◽  
pp. 73-76 ◽  
Author(s):  
Domenico De Maio ◽  
Alessandro Levi-Minzi
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Lower Incidence ◽  
Depression Scale ◽  
The Third ◽  
Depressed Patients ◽  
Self Rating

SummaryThree groups of neurotic depressed patients were treated with amitriptyline, one group receiving the customary three daily doses, another a single dose in the morning, and the third a single dose at night. All three groups showed significant decrements of total scores on the Hamilton Scale for Depression and the Zung Self-Rating Depression Scale without significant differences. Patients taking the drug at night showed a lower incidence of side effects.

A Sequential Trial Comparing Two Plasma Levels of Nortriptyline

1974 ◽  
Vol 8 (1) ◽  
pp. 21-23 ◽  
Author(s):  
Graham Burrows ◽  
L. R. Turecek ◽  
Brian Davies ◽  
Robert Mowbray ◽  
Bruce A. Scoggins
Keyword(s):  
Plasma Levels ◽  
Treatment Regimes ◽  
Sequential Trial ◽  
Depressed Patients ◽  
Significant Difference ◽  
Severity Of Depression

Pairs of depressed patients were matched for age, sex, and severity of depression, and treated for four weeks with nortriptyline so that plasma levels of below 49 ng/ml and above 140 ng/ml were, obtained. Comparisons of pairs of patients as regards to improvement of depression, using a sequential skew restricted design, suggested that it was unlikely that a significant difference between the two treatment regimes would be detected.

Characteristics and outcome of methadone maintenance treatment (MMT) patients with depression

2016 ◽  
Vol 33 (S1) ◽  
pp. S311-S312
Author(s):  
E. Peles ◽  
A. Sason ◽  
E. Malik ◽  
S. Schreiber ◽  
M. Adelson
Keyword(s):  
Suicide Attempts ◽  
Methadone Maintenance ◽  
Depression Scale ◽  
Hamilton Depression Scale ◽  
Depressed Patients ◽  
Scale Scores ◽  
First Year Retention ◽  
Competing Interest ◽  
Retention In Treatment ◽  
One Year

IntroductionComorbidity of depression and opioid addiction is highly prevalent, but their outcome in MMT is not consistent.ObjectivesTo compare between depressed and non-depressed MMT patients.MethodsHamilton depression scale scores (taken during a psychiatric assessment) were studied among MMT patients on admission or during treatment (cutoff for depression > 18).ResultsA total of 498 MMT patients were studied. Depression proportion was 22.5%, and 23.2% among 263 who were studied on admission; the depressed vs. non-depressed on admission did not differ in female proportion (19.7% vs. 25.6%), age of admission (43.2 ± 10.4), opiate use onset (21.8 ± 6.3) and education years (9.5 ± 2.8), but had higher proportion of cocaine (55.7% vs. 35.1%, P = 0.005), and benzodiazepine abuse (73.8% vs. 58.4%, P = 0.04). Retention was high and similar (80.3 vs. 82.9% P = 0.7) and of those who stayed one year, cocaine and benzodiazepine were still higher among the depressed patients (cocaine: 43.8% vs. 23.2%, P = 0.03; BDZ: 61.2% vs. 40%, P = 0.01). Compared to the non-depressed, among all study group (n = 498) the depressed patients presented higher proportion of rape history (25% vs. 9.5%, P = 0.001), of suicide attempts (43.8% vs. 25%, P = 0.001) with only a trend of shorter cumulative retention in MMT of mean 9.4y (95% CI 7.8–10.7) vs. 11.5 (95% CI 10.5–12.5, P = 0.07).ConclusionDespite cocaine and benzodiazepine abuse on admission, depressed succeeded similarly to the non-depressed in the first year retention in treatment. Intervention is recommended since admission, as their long-term retention seems to be shorter, later on, and their ability to discontinue cocaine and benzodiazepine abuse is clearly hampered.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen - eine weitere Expertenmeinung

2019 ◽  
Vol 7 (2) ◽  
pp. 77-79
Author(s):  
Uwe Gieler
Keyword(s):  
Clinical Response ◽  
Response Rate ◽  
Depression Scale ◽  
Female Gender ◽  
Anxiety Symptoms ◽  
Anxiety And Depression ◽  
Depression Symptoms ◽  
Etanercept Treatment ◽  
Depressed Patients ◽  
Pasi Score

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADSAnxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

scholarly journals Gut Microbiome Composition Associated With Major Depressive Disorder and Sleep Quality

2021 ◽  
Vol 12 ◽  
Author(s):  
Qi Zhang ◽  
Yajun Yun ◽  
Huimei An ◽  
Wenxuan Zhao ◽  
Ting Ma ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Gut Microbiota ◽  
Depressive Disorder ◽  
Sleep Quality ◽  
Critical Role ◽  
Depression Scale ◽  
Hamilton Depression Scale ◽  
Major Depressive ◽  
Severity Of Depression ◽  
Insomnia Severity

The microbiota–gut–brain axis plays a critical role in the pathogenesis of major depressive disorder (MDD) and related subclinical symptoms. However, studies on the gut microbiota in MDD are inconsistent, and data on MDD's effects on sleep are lacking. This study aimed to analyze the gut microbiota composition and sleep quality of patients with MDD. We performed 16S rRNA sequencing of stool samples from 36 patients with MDD and 45 healthy controls (HC). Sleep quality was assessed using the Pittsburgh Sleep Quality Index, depressive severity with the Hamilton Depression Scale, and insomnia severity using the Insomnia Severity Index. Forty-eight microbiota targets showed significant differences between MDD and HC. In MDD, six microbiota targets were associated with the severity of depression, 11 with sleep quality, and 3 with sleep severity. At the genus level, Dorea was simultaneously related to depression and sleep quality, while Intestinibacter was more closely related to sleep problems. Coprococcus and Intestinibacter were associated with sleep quality independent of the severity of depression. In conclusion, the present findings enable a better understanding of the relationship between gut microbiota and MDD-related symptoms. Gut microbiota alterations may become potential biomarkers and/or treatment targets for sleep quality in MDD.

scholarly journals Inflammatory versus Anti-Inflammatory Profiles in Major Depressive Disorders—The Role of IL-17, IL-21, IL-23, IL-35 and Foxp3

2021 ◽  
Vol 11 (2) ◽  
pp. 66
Author(s):  
Małgorzata Gałecka ◽  
Katarzyna Bliźniewska-Kowalska ◽  
Agata Orzechowska ◽  
Janusz Szemraj ◽  
Michael Maes ◽  
...  
Keyword(s):  
Gene Expression ◽  
Mrna Expression ◽  
Depressive Disorders ◽  
Inflammatory Diseases ◽  
Depression Scale ◽  
Inflammatory Factors ◽  
Control Group ◽  
Hamilton Depression Scale ◽  
Major Depressive Disorders ◽  
Severity Of Depression

Background: The authors of this research study intended to verify whether there are any changes in gene expression in depressed patients without coexisting inflammatory diseases for selected immune-inflammatory factors that are particularly important in autoimmune disease pathogenesis (IL-17, IL-21, IL-23, IL-35, Foxp3). Methods: The study was carried out on a group of 190 patients with depression and 100 healthy volunteers. The severity of depressive symptoms was assessed using the Hamilton Depression Scale. RT-PCR was used to evaluate mRNA expression and ELISA was used to measure protein expression of these genes. Results: The level of gene expression for IL-17, IL-21, IL-23, and IL-35 was substantially higher in the group of patients with depression compared to the control group. The mean mRNA expression of Foxp3 was considerably reduced in patients suffering from depressive disorders. There was a statistically significant correlation between the number of hospitalizations and the expression of specific inflammatory factors. Conclusions: Expression of specific inflammatory genes may be a factor in the etiopathogenesis of depressive disorders. The duration of the disease seems to be more important for the expression of the genes in question than the severity of depression. These cytokines may affect the metabolism of neurotransmitters and neuroendocrine functions in the brain as well as be a marker and a new potential therapeutic target for recurrent depressive disorders.

Sign in / Sign up

Export Citation Format

Share Document